Prevention & lipidsCross-sectional study

Factors associated with elevated high-sensitivity C-reactive protein levels in individuals with atherosclerotic cardiovascular disease in the USA and the UK

Eur J Prev CardiolPublished

  • Cross-sectional study

Authors' conclusion

The factors identified may support data-driven targeted testing to identify those most likely to have elevated hsCRP, who could potentially benefit from emerging anti-inflammatory therapies.

Study context

Population
Individuals with atherosclerotic cardiovascular disease (ASCVD) in the UK Biobank and US National Health and Nutrition Examination Survey (NHANES)
Participants
23,045 vs 3,415
Exposure
UK Biobank vs NHANES
  • UK Biobankn = 23,045
  • NHANESn = 3,415
Outcome
Factors associated with elevated hsCRP (2-10 mg/L)

Main finding

As reported in the abstract

Odds of elevated hsCRP (2-10 mg/L), multivariable logistic regression
Odds ratio (95% CI)P value
obesityUK Biobank
3.48(3.18–3.80)
P < 0.05
obesityNHANES
4.11(2.66–6.34)
P < 0.05
overweightUK Biobank
1.56(1.44–1.70)
P < 0.05
overweightNHANES
2.26(1.51–3.38)
P < 0.05
current smokerUK Biobank
2.47(2.27–2.69)
P < 0.05
current smokerNHANES
1.96(1.23–3.10)
P < 0.05
female sexUK Biobank
1.69(1.59–1.80)
P < 0.05
female sexNHANES
1.69(1.24–2.31)
P < 0.05
increased LDL cholesterolUK Biobank; per 10 mg/dL increase
1.05(1.04–1.06)
P < 0.05
increased LDL cholesterolNHANES; per 10 mg/dL increase
1.00(1.00–1.00)
P < 0.05
increased triglyceride levelsUK Biobank; per 10 mg/dL increase
1.01(1.01–1.01)
P < 0.05
increased triglyceride levelsNHANES; per 10 mg/dL increase
1.00(1.00–1.00)
P < 0.05
Receiving statinsUK Biobank; lower odds
0.69(0.64–0.75)
Receiving statinsNHANES; lower odds
0.54(0.39–0.74)

Per 10 mg/dL increase, as printed

Observational data: associations, not effects.

Further findings

High-sensitivity C-reactive protein (hsCRP) by number of combined factors (incl. CKD stage G3-5)

hsCRP higher in individuals with more factors
  • median with seven factors

Original publication

Factors associated with elevated high-sensitivity C-reactive protein levels in individuals with atherosclerotic cardiovascular disease in the USA and the UK. Eur J Prev Cardiol. Published 1 October 2025. doi:10.1093/eurjpc/zwaf609

Summarised from the published abstract; every number is checked against it